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Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains one of the world’s
largest infectious disease problems. Despite decades of intensive study, the immune
response to Mtb is incompletely characterised, reﬂecting the extremely complex interac-
tion between pathogen and host. Pathways that may alter the balance between host
protection and pathogenesis are therefore of great interest. One pathway shown to play a
role in the pathogenesis of chronic infections, including TB, is the programmed death-1
(PD-1) pathway. We show here that the expression of the programmed death ligand 1
(PD-L1), which interacts with PD-1, is increased in whole blood from active TB patients
compared with whole blood from healthy controls or Mtb-exposed individuals, and that
expression by neutrophils is largely responsible for this increase.
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Introduction
Infection with Mycobacterium tuberculosis (Mtb), leading to
tuberculosis (TB), remains one of the pre-eminent problems in
global health, with an estimated third of the world’s population
infected with Mtb [1]. The majority of infected people remain in a
state of ‘latency’, being asymptomatic and non-infectious, as the
infection is controlled by the immune response. Nonetheless, a
small proportion of infected individuals will suffer active disease
or reactivate latent infection resulting in active disease [2].
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understood. Several factors are known to be necessary for control
of Mtb but there is an incomplete understanding of which host
factors are sufﬁcient for successful immune control or which
drive disease pathogenesis [2, 3]. Therefore, there is great
interest in how immune regulatory systems may modulate the
balance between protection and pathogenesis during TB.
Programmed death ligand 1 (PD-L1) (also denoted as CD274
and B7-H1) is an immunomodulatory molecule that acts largely
through interaction with the programmed death-1 (PD-1)
receptor [4]. PD-1 interacts with its ligands PD-L1 and PD-L2 to
deliver inhibitory signals that regulate T-cell and other responses,
thus helping to maintain the balance between effective immunity,
tolerance and immuno-pathology. PD-L1 is reportedly expressed
on a variety of different cell types, including T cells and myeloid
cells such as DCs and monocytes [4].
PD-L1/PD-1 interactions can play a role in a diverse array of
settings including infectious disease. In an infectious setting,
PD-L1/PD-1 interactions are often associated with chronicity,
particularly during viral infection [4]. PD-L1 reportedly
suppresses T-cell proliferation and effector function, through
binding PD-1, most notably on functionally ‘exhausted’ CD8
1
T cells during chronic viral infections such as mouse models of
lymphocytic choriomeningitis virus infection and also on CD4
1
and CD8
1 T cells in patients infected with HIV or hepatitis C
[5–9].
PD-L1/PD-1 interactions may also play a role in the chronicity
of some bacterial infections [10, 11]. T cells from TB patients
reportedly express PD-1, and PD-L1 could be induced on T cells
stimulated with sonicated H37Rv Mtb [12]. Antibodies blocking
PD-1/PD-L1/PD-L2 enhanced Mtb antigen-speciﬁc IFN-g respon-
ses and CD8
1 T-cell cytotoxicity from peripheral blood and
pleural ﬂuid mononuclear cells in vitro [12]. Similar ﬁndings
have recently been reported for NK cells obtained from pleural
ﬂuid and peripheral blood of TB patients [13]. Nevertheless, the
expression of PD-1 and its ligands PD-L1 and PD-L2 during TB
remains incompletely deﬁned, thus hampering the understanding
of how PD-L1/PD-1 may regulate the immune response to Mtb.
We have previously conducted whole genome microarray of
whole blood from active and latent TB patients and healthy
controls and shown a distinct transcriptional signature,
comprising both under and over-represented transcripts, for the
active TB group [14]. We wished to further investigate these data
sets to determine the levels of expression of molecules of the PD-1
pathway in different cell populations in patients with TB.
Results
PD-L1 is over-represented in active TB patients’ blood
and reduced with anti-mycobacterial treatment
Initially, we investigated the expression of transcripts for the
main molecules involved in the PD-1 pathway, namely PD-1, PD-
L1 and PD-L2, in whole blood from active and latent TB patients
and healthy controls (Fig. 1A). PD-L1 was signiﬁcantly over-
represented in whole blood from active TB patients as compared
with healthy controls and latent TB patients in three independent
cohorts of patients (Fig. 1A); two recruited in London (Training
and Test sets, p50.0043 and 0.000521, respectively) and one
from a TB endemic area (South Africa; validation set, po 0.0001).
The abundance of PD-L2 was increased in some active TB
patients, particularly in the training set; however, PD-L2 levels
overall were not signiﬁcantly different in all three cohorts (Fig.
1A). PD-1 levels were not increased in active TB patients
compared with latent TB patients and healthy controls in all
three cohorts (Fig. 1A and data not shown).
In addition, we investigated how PD-L1 levels were affected
during successful treatment of disease with anti-mycobacterial
chemotherapy. Seven active TB patients were tracked longitudinally
during anti-mycobacterial treatment and PD-L1 levels assessed at
time of diagnosis and at 2 and 12 months after initiation of treat-
ment. The over-representation of PD-L1 in blood of active TB
patients seen at the time of diagnosis was signiﬁcantly decreased
with treatment (Fig. 1B). One patient did not have increased levels
of PD-L1 at time of diagnosis; however, upon further clinical
analysis, this patient showed no radiographic disease [14]. Although
some active TB patients still showed elevated levels of PD-L1 trans-
cripts at 2 months post-initiation of treatment, there was no
difference in PD-L1 transcript levels in patients compared with
healthy controls after completing successful therapy (Fig. 1B).
Together, these ﬁndings suggest that the presence of PD-L1 in
the blood may be related to pathology and failure to control
disease during TB. In this regard, our ﬁndings would be consis-
tent with reports both in murine models and human studies of
chronic viral and bacterial infections [5–13, 15, 16].
PD-L1 is upregulated on the cell surface of blood
leucocytes from active TB patients
To elucidate whether the over-representation of PD-L1 in blood
of active TB patients resulted from a general increase in numbers
of cells expressing PD-L1 or from increased expression of PD-L1
by a particular cell type, ﬂow cytometric analysis of blood from
test set active TB patients and healthy controls was conducted.
There was variation between patients, reﬂected by spread in MFI
of PD-L1 expression (Fig. 2A), likely representing the hetero-
geneity of TB patients, extent of disease and the natural
variability in the human immune response to Mtb. However,
overall expression of PD-L1 on whole blood leucocytes from
patients with active TB was signiﬁcantly increased compared with
blood leucocytes from healthy controls (Fig. 2A; Supporting
Information Fig. 1A), in line with the microarray ﬁndings.
Neutrophils are the predominant cell type expressing
PD-L1 in blood of active TB patients
Since PD-L1 expression was increased on a proportion but not all
leucocytes from blood of active TB patients, we were interested to
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ﬂow cytometric analysis revealed that PD-L1 was most highly
expressed on cells that were consistent with CD16
1 neutrophils,
whereas few cells consistent with CD14
1 monocytes or CD3
1 or
CD19
1 lymphocytes from active TB patients expressed PD-L1
(Fig. 2B; Supporting Information Fig. 1B). Again, relatively low
levels of expression of PD-L1 were found on all analysed cell
types from the blood of healthy controls (Fig. 2B; Supporting
Information Fig. 1B).
To conﬁrm the increased level of neutrophil-speciﬁc PD-L1
expression in active TB patients, neutrophils, monocytes, CD4
1
and CD8
1 T cells from blood of active TB patients and healthy
controls were separated using magnetic beads, and the levels of
PD-L1 transcripts determined using Nanostring nCounter tech-
nology (Fig. 2C). This technology allows capture and counting of
individual mRNA transcripts in a complex mixture and has similar
sensitivity to real-time PCR [17]. Nanostring analysis of puriﬁed
cell populations showed that puriﬁed neutrophils from active TB
patients expressed signiﬁcantly higher levels of PD-L1 transcripts
than puriﬁed neutrophils from healthy controls (Fig. 2C), and
this increased expression on neutrophils appeared to account for
the total increase in PD-L1 expression in whole blood. Monocytes
from active TB patients also had slightly higher expression of
PD-L1 than monocytes from healthy controls, and although levels
were signiﬁcant they were much lower than in whole blood or
neutrophils. There was no increased PD-L1 expression in CD4
1
and CD8
1 T cells above controls (Fig. 2C). Thus, neutrophils
appear to be the predominant cell type over-expressing PD-L1 in
the blood of active TB patients.
To our knowledge, this is the ﬁrst report of PD-L1 expression
by neutrophils during in vivo infection, although a recent report
has shown that treatment of neutrophils with IFN-g and GM-CSF
upregulated PD-L1 [18] and an earlier report showed that LPS
stimulation could upregulate PD-L1 on neutrophils [19]. We have
previously found that neutrophils from active TB patients display
an IFN-inducible signature that contained gene transcripts
involved in both type I and type II IFN signalling [14]. Our results
are therefore consistent with these earlier ﬁndings [18] but also
Figure 1. PD-1, PD-L1 and PD-L2 gene expression in active TB and during anti-mycobacterial treatment. (A) PD-1, PD-L1 and PD-L2 gene transcript
abundance in whole blood samples from active TB patients, latent TB patients and healthy controls. (B) PD-L1 transcript abundance in whole blood
samples from seven active TB patients at the time of diagnosis and at 2 and 12 months post-initiation of anti-mycobacterial treatment, compared
with healthy controls, shown by heatmap and graph. Gene abundance is shown normalised to the median of all samples. Each row of the
heatmaps represents an individual gene and each column an individual participant. The relative abundance of transcripts is indicated by a colour
scale (red, high; yellow, median; blue, low). Each point on the graph represents one subject and the line and error bars the mean and 95%
conﬁdence interval. Statistical signiﬁcance was analysed using (A) Kruskal–Wallis one-way ANOVA with Benjamini–Hochberg multiple testing
correction (PD-L1: active versus latent and control, training set p50.0043, test set p50.000521, validation set p o 0.0001) and (B) Friedman test with
Dunn’s post hoc analysis.
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Figure 2. Levels of PD-L1 in different cell populations from whole blood. (A) Whole leucocytes from 11 healthy controls and 11 active TB patients
were stained with anti-PD-L1 antibodies and expression levels determined. An example of a healthy control and active TB patient are shown.
(B) Gates were then set on cells representing neutrophils, monocytes and lymphocytes, which were assessed for PD-L1 expression. Different cell
subpopulations are shown in blue; total leucocytes in red and isotype control (total cells) in green. Isotype levels on separated cells were not
different to levels on total cells (data not shown). Neutrophils were deﬁned as CD16
1CD14
– forward scatter (FSC) high, side scatter (SSC) high,
monocytes as CD14
1 FSC intermediate SSC intermediate and lymphocytes as CD3
1CD19
1 FSC low, SSC low. Graphs for (A) and (B) show pooled
data of the geometric mean ﬂuorescence intensity of PD-L1 on each subset for all subjects. Each symbol represents one subject; lines and error
bars the mean and 95% conﬁdence interval. Statistical signiﬁcance was analysed using unpaired t-test. (C) Whole blood, separated neutrophils,
monocytes and CD4
1 and CD8
1 cells from seven active TB patients and four healthy controls were analysed by Nanostring technology for PD-L1
gene expression. Graphs show pooled data of PD-L1 expression for each subset. Each symbol represents one subject; lines and error bars the mean
and 95% conﬁdence interval. Statistical signiﬁcance was analysed using Mann–Whitney t-test.
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neutrophils, particularly as type I IFN reportedly upregulates
PD-L1 on other cell types [20, 21].
How PD-L1 expression on neutrophils modulates the immune
response during TB remains to be elucidated; however, it is
possible that PD-L1 expression acts as a mechanism for limiting
neutrophil-mediated immunopathology. This is in accordance
with recent ﬁndings that PD-1
/ mice infected with Mtb have
severe lung pathology and succumb to disease much earlier than
WT mice [22]. This was associated with a dramatic increase in
neutrophils in the lungs [22].
Concluding remarks
In this study we show that the immunomodulatory ligand PD-L1
is over-represented in the blood of patients with active TB, that
this over-representation is largely driven by neutrophil expression
of PD-L1 and is diminished by successful therapy. This is
consistent with an association of PD-L1 with failure to control
disease and pathology. Whether PD-1/PD-L1 interactions act to
suppress protective immunity during TB or as a mechanism for
controlling neutrophil-mediated immunopathology will be
important to elucidate. The majority of studies of PD1/PD-L1
interaction during chronic viral infection point to this pathway
acting to suppress protective CD8
1 T-cell responses [5–8]. PD-1/
PD-L1 interaction may also therefore suppress protective
responses during TB [12, 13]. Indeed, there is evidence that the
PD-1/PD-L1 pathway suppresses Mtb-speciﬁc IFN-g production
and cytotoxicity by T cells as well as IFN-g production and
cytotoxicity by NK cells from peripheral blood and pleural ﬂuid
mononuclear cells from TB patients [12, 13]. Whether neutro-
phils expressing PD-L1 are able to suppress these protective
responses in active TB patients would be important to investigate.
However, there is growing evidence that in intracellular
bacterial infections, where protection is largely mediated by
CD4
1 T cells, the role of the PD-1/PD-L1 pathway may be less
straightforward. Two models of Listeria infection demonstrated
that abrogation of PD-L1 signalling during infection led to
reduced antigen-speciﬁc T-cell responses, inhibition of key
effector molecules, increased bacterial loads and increased
mortality [23, 24]. In addition, recent reports have shown that
PD-1
/ mice infected with Mtb also have signiﬁcantly higher
bacterial loads in the lung, increased lung pathology and earlier
mortality than wild-type mice [22, 25]. Large increases in pro-
inﬂammatory cytokines and an increase in neutrophils but a
decrease in T cells in the lungs were also observed [22]. Another
report has shown that PD-1 expressing CD4
1 T cells during
murine Mtb infection are not analogous to the functionally
exhausted PD-1-expressing CD8
1 T cells seen during chronic viral
infections but rather are a highly proliferating, cytokine-produ-
cing population [26]. The effect of PD-1/PD-L1 interactions on
innate and adaptive immunity during bacterial infection is
therefore likely to be more complex than at ﬁrst thought and this
may complicate their use as a potential therapeutic target.
Materials and methods
Patient cohorts and healthy controls, sample collection
and processing for microarray
This study was approved by the local Research Ethics Committees at
St Mary’s Hospital London, UK (REC 06/Q0403/128) and
University of Cape Town, Cape Town, Republic of South Africa
(REC012/2007). All participants were over 18 years of age and gave
written informed consent. See Berry et al. [14] for further details.
Blood (3mL) was collected into Tempus tubes (Applied
Biosystems, CA, USA) and stored between 20 and 801C. All
patients were sampled before treatment. The diagnosis of active
TB was conﬁrmed by positive culture for Mtb. Latent TB patients
were asymptomatic household contacts of active TB patients or
new entrants from endemic countries, deﬁned by a positive
tuberculin-skin test (TST) (London) and a positive Mtb antigen-
speciﬁc Interferon-g Release Assay (London and South Africa;
QuantiFERON Gold In-Tube Assay, Cellestis). Ethnically matched
healthy controls were recruited in London and were negative for
all the above criteria. The cohorts were independently recruited
and sampled. RNA preparation, all processing and analysis of
samples from the three cohorts were performed independently.
Genome-wide transcriptional proﬁles from the blood of active TB
patients, latent TB patients and healthy controls were generated
using Illumina HT12 V3 beadarrays as previously described [14].
Micorarray data analysis
Illumina BeadStudio v2 software was utilised to subtract
background and scale average signal intensity for each sample
to the global average signal intensity for all samples. Further
normalisation was performed using the gene expression analysis
software program, GeneSpring GX, version 7.1.3 (Agilent
Technologies, Santa Clara, CA, USA). All signal intensity values
o10 were set equal to 10. Per-gene normalisation was then
applied by dividing the signal intensity of each probe in each
sample by the median intensity for that probe across all samples.
Flow cytometry
Antibody staining of whole blood for ﬂow cytometry was
performed as previously described [14]. Samples were run on a
Beckman Coulter CyAn using Summit Software Version 3.02. All
antibodies were purchased from BD Pharmingen or Caltag
Laboratories (Invitrogen). Analysis was carried out using FlowJo
Version 8.7.3 for Macintosh (Tree Star).
Cell separation and RNA preparation
Cell separations and subsequent RNA preparation were
performed as previously described [14]. Samples were then
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GeneSpring GX7.3.1 software.
Gene expression analysis using Nanostring technology
The nCounter Analysis System (Nanostring) [17] was used to
validate gene expression seen previously by microarray analysis.
mRNA was detected using a custom-made nCounter Reporter
probe set (84 transcripts). A total of 100ng total RNA was
hybridised overnight at 651C in a thermocycler to reporter and
capture probe sets to form target/probe complexes. Following
hybridisation, excess probes were washed away on the nCounter
Prep Station. Colour-coded barcodes on the reporter probe were
read on an nCounter Digital Analyser to give a quantitative
measure of RNA. Using Microsoft Excel, samples signal values
were scaled and normalised to the positive control spikes, and
then background subtracted. All signal intensity values o10 were
set equal to 10.
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